Diabetes Mellitus clinical trials

The registry lists 8,291 studies for Diabetes Mellitus across more than 10 countries. 1,075 are recruiting or about to start. 3,462 of them are mainly about Diabetes Mellitus (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its 14 narrower conditions too, such as Diabetes Mellitus, Type 2: 23,020 studies, 3,493 open.

ClinicalTrials.gov finds 24,618 studies for Diabetes Mellitus. How that becomes 8,287 here

This page counts the studies the registry files under Diabetes Mellitus, and those it files under no condition that list Diabetes Mellitusthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

24,618Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
−14,511Filed under a narrower condition, counted on its own pageDiabetes Mellitus, Type 2 8,050 · Diabetes Mellitus, Type 1 2,626 · Diabetic Foot 785 · Diabetes, Gestational 693 · Prediabetic State 586 · Diabetic Retinopathy 501 · 8 more
−159List Diabetes Mellitus as a condition, but the registry did not file them under itMost often written as “Type2 Diabetes Mellitus” (28), “Glucose Metabolism Disorders (Including Diabetes Mellitus)” (16), and “Type1 Diabetes Mellitus” (11). The registry filed them under other conditions only, most often Obesity (33) and Insulin Resistance (17).
−1,661Match it another way232 name it in the title, 13 in a keyword, and 1,416 by a synonym or other text the search reads.
8,287The count on this page62 of them list Diabetes Mellitus in their own words; the registry filed them under no condition.

Get an email when these change. Save the Diabetes Mellitus studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 5,412
Status unknown: 883
Recruiting: 649
Terminated: 414
Not yet recruiting: 331
Active, not recruiting: 256

Phase

Phase 3: 789
Phase 2: 743
Phase 4: 741
Phase 1: 719
Early Phase 1: 51

Where

United States: 3,022
Germany: 512
Canada: 493
United Kingdom: 462
China: 417
France: 352

Who runs them

Novo Nordisk A/S (642) · AstraZeneca (117) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (80) · Takeda (70) · Emory University (60) · VA Office of Research and Development (58) · National Heart, Lung, and Blood Institute (NHLBI) (53) · US Department of Veterans Affairs (49)

What is being tested here

Drugs under test in Diabetes Mellitus studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Semaglutide	12	27	82
Dapagliflozin	8	18	51
Empagliflozin	8	4	39
Tirzepatide	8	4	14
Metformin	7	36	112
Pioglitazone	4	16	57
Insulin Glargine	2	25	81
Insulin, Regular, Human	2	18	41
Atorvastatin	2	2	24
Glucagon	2	4	17

Drug classes tested here GLP-1 receptor agonists 20 open · SGLT2 inhibitors 19 open · DPP-4 inhibitors 4 open · Statins 3 open · Angiogenesis inhibitors 3 open

Coming up

45phase 3 studies under way

358studies finish main data collection within a year10 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Nov 2026A Phase IIIb Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin · Phase 3 · Gan & Lee Pharmaceuticals.
Dec 2026Trial to Assess Chelation Therapy in Critical Limb Ischemia · Phase 3 · Mt. Sinai Medical Center, Miami
Dec 2026Comparison Between Efficacy of Trelagliptin and Sitagliptin in Type II Diabetic Patients · Phase 3 · Khyber Medical College, Peshawar
Jan 2027Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide · Phase 3 · McGill University Health Centre/Research Institute of the McGill University Health Centre
Mar 2027Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments · Phase 3 · Consorcio Centro de Investigación Biomédica en Red (CIBER)
Mar 2027The Prospective, Double-blind, Multicenter, Placebo-controlled, Randomized, Comparative Clinical Trial · Phase 3 · JSC NextGen
Apr 2027Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF) · Phase 3 · University of Oklahoma
Jul 2027Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy · Phase 3 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Aug 2027Bridge Study to Evaluate the Efficacy and Safety of IN-B00009 Injection in Patients With T2DM Inadequately Controlled by Diet and Exercise Alone · Phase 3 · HK inno.N Corporation
Oct 2027A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) · Phase 3 · Pfizer

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 197 (30%) stop at 75 or younger. 88 (14%) take children under 18. 31 (5%) are for women only and 9 (1%) for men only; 183 (28%) take healthy volunteers.

Recruiting studies that take each age, of 649
Age	Women	Men
10	68 (10%)	66 (10%)
18	477 (73%)	457 (70%)
30	542 (84%)	519 (80%)
40	560 (86%)	541 (83%)
50	569 (88%)	556 (86%)
65	554 (85%)	545 (84%)
75	486 (75%)	477 (73%)
85	405 (62%)	397 (61%)

Across all 8,291 studies, recruiting or not: 40% stop at 75 or younger and 24% at 65; 13% take children; 4% are for women only and 4% for men only; 25% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Diabetes Mellitus studies take

Of 247 phase 1 interventional studies under Diabetes Mellitus, half reached primary completion within 7 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	7 mo3–17 · 247 studies	6 mo2–10 · 171 studies	19 mo8–55 · 76 studies
Phase 1/2	34 mo21–60 · 40 studies	—	—
Phase 2	27 mo12–51 · 147 studies	14 mo8–28 · 65 studies	45 mo21–100 · 82 studies
Phase 2/3	27 mo16–56 · 23 studies	—	—
Phase 3	19 mo13–35 · 230 studies	17 mo12–23 · 167 studies	41 mo26–79 · 63 studies
Phase 4	24 mo13–40 · 197 studies	16 mo10–22 · 48 studies	29 mo15–53 · 149 studies
Interventional, no phase	21 mo9–42 · 1,744 studies	13 mo4–26 · 160 studies	23 mo10–43 · 1,584 studies
Observational	36 mo14–122 · 642 studies	21 mo6–39 · 109 studies	42 mo16–159 · 533 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out